The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice
Authors:
Open Access
- 1 March 2021
- journal article
- research article
- Published by Elsevier in Molecular Therapy-Oncolytics
- Vol. 20, 556-568
Abstract
No abstract availableKeywords
Funding Information
- Science and Technology Commission of Shanghai Municipality (19ZR1454700)
- Science and Technology Commission of Shanghai Municipality (202H1020600)
This publication has 33 references indexed in Scilit:
- Establishment of patient-derived cancer xenografts in immunodeficient NOG miceInternational Journal of Oncology, 2015
- Establishment of a Patient-Derived Orthotopic Xenograft (PDOX) Model of HER-2-Positive Cervical Cancer Expressing the Clinical Metastatic PatternPLOS ONE, 2015
- In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cellsScience Translational Medicine, 2015
- Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic AlterationsCancer Research, 2014
- CAR T Cells for Solid TumorsThe Cancer Journal, 2014
- CAR–T cells and solid tumors: tuning T cells to challenge an inveterate foeTrends in Molecular Medicine, 2012
- Survival for Ovarian Cancer in Europe: The across-country variation did not shrink in the past decadeActa Oncologica, 2012
- Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domainsProceedings of the National Academy of Sciences, 2009
- Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.Proceedings of the National Academy of Sciences, 1996
- Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.Proceedings of the National Academy of Sciences, 1989